Vanguard Group Inc Buys 22,510 Shares of Unum Therapeutics Inc (UMRX)

Vanguard Group Inc raised its stake in Unum Therapeutics Inc (NASDAQ:UMRX) by 4.2% during the third quarter, Holdings Channel reports. The institutional investor owned 552,380 shares of the company’s stock after buying an additional 22,510 shares during the quarter. Vanguard Group Inc’s holdings in Unum Therapeutics were worth $5,690,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of UMRX. Jane Street Group LLC bought a new stake in shares of Unum Therapeutics during the third quarter valued at about $150,000. Bank of New York Mellon Corp acquired a new stake in Unum Therapeutics in the 2nd quarter worth approximately $177,000. JPMorgan Chase & Co. lifted its holdings in Unum Therapeutics by 2,782.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 20,753 shares of the company’s stock worth $213,000 after purchasing an additional 20,033 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Unum Therapeutics in the 3rd quarter worth approximately $235,000. Finally, Northern Trust Corp acquired a new stake in Unum Therapeutics in the 2nd quarter worth approximately $620,000. Institutional investors own 51.07% of the company’s stock.

Shares of UMRX stock traded up $0.03 during trading hours on Monday, hitting $4.26. 721 shares of the company’s stock were exchanged, compared to its average volume of 131,619. Unum Therapeutics Inc has a 52 week low of $3.60 and a 52 week high of $17.66.

Unum Therapeutics (NASDAQ:UMRX) last issued its quarterly earnings results on Monday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01. Unum Therapeutics had a negative return on equity of 382.71% and a negative net margin of 404.34%. The business had revenue of $2.04 million for the quarter, compared to analyst estimates of $2.29 million. As a group, equities analysts predict that Unum Therapeutics Inc will post -1.56 EPS for the current year.

In other news, insider Seth Ettenberg sold 11,485 shares of the company’s stock in a transaction on Monday, November 26th. The stock was sold at an average price of $7.00, for a total transaction of $80,395.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Several analysts have recently commented on the company. Zacks Investment Research upgraded Unum Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 30th. HC Wainwright assumed coverage on Unum Therapeutics in a report on Thursday, December 20th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Cowen restated a “hold” rating on shares of Unum Therapeutics in a report on Monday, November 19th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $20.00.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

Further Reading: What is the price-sales ratio?

Want to see what other hedge funds are holding UMRX? Visit to get the latest 13F filings and insider trades for Unum Therapeutics Inc (NASDAQ:UMRX).

Institutional Ownership by Quarter for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply